Columbus Interim Report Q1 2025

Seeking Alpha / 1 hour ago 1 Views

Company announcement no. 5/2025

CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1)

3 hours from now
STRATA Skin Sciences to Participate in the D. Boral Capital Inaugural Global Conference

3 hours from now
ZenaTech’s ZenaDrone Tests Proprietary Camera Enabling IQ Nano Drone Swarms for US Defense Applications and Blue UAS Submission

3 hours from now
21Shares AG - Publication of Base Prospectus

3 hours from now
NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally Invests $2.65 Million Cash to Accelerate Phase 2 Clinical Trial and Fulfill Financial Reporting Obligations

3 hours from now